SCHEMBL2964600

SCHEMBL2964600

CCOC(=O)c1ccc2c(c1)ncn2-c1cccc(COC(C)c2ncc[nH]2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
FGFR1 P11362 3/20 0.45
KMT2A Q03164 2/20 0.43
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
RAB9A P51151 1/20 0.40
TBXAS1 P24557 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652428 0.84 HPGD (0.45) HPGDSMN1; SMN2MAPK1FGFR1KMT2A
SCHEMBL2974092 0.83 FGFR1 (0.38) HPGDSMN1; SMN2MAPK1FGFR1GABRA1
SCHEMBL2977950 0.82 FGFR1 (0.39) SMN1; SMN2MAPK1FGFR1GABRA1GABRG2
SCHEMBL2966390 0.82 FGFR1 (0.44) HPGDSMN1; SMN2MAPK1FGFR1ALDH1A1
SCHEMBL2976805 0.82 PRKCI (0.44) SMN1; SMN2MAPK1FGFR1GABRA1GABRG2
SCHEMBL2652696 0.80 FGFR1 (0.36) HPGDSMN1; SMN2MAPK1FGFR1GABRA1
SCHEMBL2652990 0.80 FGFR1 (0.57) HPGDSMN1; SMN2MAPK1FGFR1KMT2A
SCHEMBL1881909 0.79 NOTUM (0.48) HPGDSMN1; SMN2KMT2AGABRA2MEN1
SCHEMBL13202768 0.79 HPGD (0.51) HPGDSMN1; SMN2MAPK1FGFR1KMT2A
SCHEMBL2652993 0.78 GABRA1 (0.54) HPGDSMN1; SMN2MAPK1FGFR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 HPGD 1855/4885SMN1; SMN2 2658/4885MAPK1 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.